Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 3Phase 1 2Phase 3 1

Status

Completed 3

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Follicular 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × obatoclax × Clear all
NCT00427856 2016-07-22

Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
7 enrolled
Lymphoid

Lymphoma, Follicular

NCT00684918 2013-08-26

Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
18 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00359892 2012-08-06

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
13 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡